Table 2.
Baseline clinical characteristics of patients stratified by major adverse cardiovascular events
| Characteristic | Non-MACE (n = 745) | MACE (n = 214) | P value |
|---|---|---|---|
| Age, mean (SD), years | 61.2 (10.6) | 63.9 (9.9) | 0.001 |
| Male, No. (%) | 556 (74.6) | 159 (74.3) | 0.993 |
| SBP, mean (SD), mmHg | 143.5 (25.0) | 134.9 (23.9) | < 0.001 |
| DBP, mean (SD), mmHg | 79.8 (13.5) | 74.9 (12.5) | < 0.001 |
| Heart rate, mean (SD), beats/min | 79.9 (14.4) | 82.4 (15.6) | 0.026 |
| Medical history and risk factors, No. (%) | |||
| Hypertension | 689 (92.5) | 201 (93.9) | 0.569 |
| Diabetes mellitus | 380 (51.0) | 129 (60.3) | 0.020 |
| Current smoker | 142 (19.1) | 39 (18.2) | 0.860 |
| Atrial fibrillation | 55 (7.4) | 26 (12.1) | 0.038 |
| Cerebrovascular disease | 133 (17.9) | 51 (23.8) | 0.063 |
| Valvular disease | 22 (3.0) | 9 (4.2) | 0.488 |
| Peripheral arterial disease | 70 (9.4) | 25 (11.7) | 0.391 |
| Cause of ESRD, No. (%) | 0.077 | ||
| Diabetes mellitus | 226 (30.3) | 78 (36.4) | |
| Hypertension | 91 (12.2) | 32 (15.0) | |
| Glomerulonephritis | 191 (25.6) | 39 (18.2) | |
| Other/unknown | 237 (31.8) | 65 (30.4) | |
| Insulin therapy, No. (%) | 246 (33.0) | 76 (35.5) | 0.549 |
| Dialysis modality, No. (%) | 1.000 | ||
| Hemodialysis | 689 (92.5) | 198 (92.5) | |
| Peritoneal dialysis | 56 (7.5) | 16 (7.5) | |
| Vintage, years | 0.331 | ||
| < 1 | 162 (21.7) | 37 (17.3) | |
| 1–5 | 337 (45.2) | 107 (50.0) | |
| 5–10 | 190 (25.5) | 58 (27.1) | |
| ≥ 10 | 56 (7.5) | 12 (5.6) | |
| Index presentation, No. (%) | < 0.001 | ||
| AMI | 413 (55.4) | 151 (70.6) | |
| Non-AMI | 332 (44.6) | 63 (29.4) | |
| Hemoglobin, g/L | 105.3 (19.9) | 105.9 (19.5) | 0.696 |
| Glucose, mmol/L | 6.0 [4.7, 8.7] | 7.9 [5.7, 10.6] | < 0.001 |
| Serum creatinine, mg/dl | 8.7 [6.7, 10.9] | 8.4 [6.7, 10.9] | 0.416 |
| TG, mmol/L | 1.6 [1.1, 2.3] | 1.6 [1.1, 2.3] | 0.585 |
| TC, mmol/L | 3.7 [3.1, 4.5] | 3.8 [3.1, 4.4] | 0.854 |
| HDL-C, mmol/L | 0.9 [0.7, 1.1] | 0.9 [0.7, 1.1] | 0.204 |
| LDL-C, mmol/L | 2.2 [1.6, 2.8] | 2.1 [1.7, 2.8] | 0.894 |
| TyG index | 9.0 [8.5, 9.5] | 9.3 [8.8, 9.8] | < 0.001 |
| Procedure characteristic, No. (%) | |||
| Radial access | 578 (77.6) | 162 (75.7) | 0.627 |
| Extent of disease | |||
| Any left main disease | 67 (9.0) | 44 (20.6) | < 0.001 |
| 2-vessel disease | 216 (29.0) | 47 (22.0) | 0.052 |
| 3-vessel disease | 391 (52.5) | 153 (71.5) | < 0.001 |
| Moderate or severe calcification | 324 (43.5) | 108 (50.5) | 0.084 |
| PCI treatment | 535 (71.8) | 141 (65.9) | 0.112 |
| Discharge medications, No. (%) | |||
| Dual antiplatelet therapy | 642 (86.2) | 194 (90.7) | 0.107 |
| ACE inhibitor or ARB | 357 (47.9) | 84 (39.3) | 0.030 |
| Beta-blocker | 597 (80.1) | 178 (83.2) | 0.369 |
| Calcium-channel blocker | 500 (67.1) | 120 (56.1) | 0.004 |
| Statin | 697 (93.6) | 202 (94.4) | 0.776 |
Data are presented as mean (SD) or n (%)
ACE, angiotensin-converting enzyme; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; DBP, diastolic blood pressure; ESRD, end-stage renal disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; TyG, triglyceride-glucose